SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (9773)12/16/2003 10:43:58 AM
From: Sam Citron  Read Replies (1) of 52153
 
9:11AM MEDI- CSFB comments on FluMist deal 27.34: On 12/15, the U.S. Dept of Health and Human Services (HHS) announced that it has purchased 3 mln doses of FluMist, at a price of $20 ea., for immediate distribution to states with insufficient supply. CSFB believes that MEDI shares have priced in the possibility that much or all of the 4.1 mln doses procured this year would be sold to health authorities. The low $20 price point is disappointing, but a necessary evil after a dismal launch. In firms view, MEDI's primary goal should be to put the vaccine into as many nostrils as possible this season, so as to create patient and physician impressions, to establish the safety profile, and to assess cross-protection. A number of physicians with who firm have spoken indicate that they do not intend to offer FluMist until its safety has been established with 2M or more doses.

www.briefing.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News